Zhitong Finance App News, Xintiandi (301277.SZ) issued an announcement. The company recently received the “Notice of Approval of the Marketing Application for Chemical Ingredient” for the active ingredient fondazepam decanoate and issued by the State Drug Administration. Fondazepam is an artificially synthesized selective coagulation factor Xa inhibitor with uniform ingredients and no animal-derived ingredients. Indications are prevention of venous thromboembolism after major orthopedic surgeries such as hip fractures and hip and knee replacements. It can also be used for anticoagulant treatment of deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.